Invivyd (IVVD) Competitors $0.52 -0.01 (-1.48%) Closing price 04:00 PM EasternExtended Trading$0.53 +0.01 (+1.90%) As of 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IVVD vs. FDMT, INBX, CADL, LRMR, RCKT, AMRN, ALDX, ALT, CTMX, and CGCShould you be buying Invivyd stock or one of its competitors? The main competitors of Invivyd include 4D Molecular Therapeutics (FDMT), Inhibrx Biosciences (INBX), Candel Therapeutics (CADL), Larimar Therapeutics (LRMR), Rocket Pharmaceuticals (RCKT), Amarin (AMRN), Aldeyra Therapeutics (ALDX), Altimmune (ALT), CytomX Therapeutics (CTMX), and Canopy Growth (CGC). These companies are all part of the "pharmaceutical products" industry. Invivyd vs. Its Competitors 4D Molecular Therapeutics Inhibrx Biosciences Candel Therapeutics Larimar Therapeutics Rocket Pharmaceuticals Amarin Aldeyra Therapeutics Altimmune CytomX Therapeutics Canopy Growth Invivyd (NASDAQ:IVVD) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings. Which has more risk and volatility, IVVD or FDMT? Invivyd has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.83, suggesting that its share price is 183% more volatile than the S&P 500. Is IVVD or FDMT more profitable? Invivyd has a net margin of -238.33% compared to 4D Molecular Therapeutics' net margin of -594,375.81%. 4D Molecular Therapeutics' return on equity of -40.15% beat Invivyd's return on equity.Company Net Margins Return on Equity Return on Assets Invivyd-238.33% -177.89% -90.96% 4D Molecular Therapeutics -594,375.81%-40.15%-36.43% Do insiders & institutionals have more ownership in IVVD or FDMT? 70.4% of Invivyd shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 25.4% of Invivyd shares are owned by insiders. Comparatively, 9.6% of 4D Molecular Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger valuation and earnings, IVVD or FDMT? 4D Molecular Therapeutics has lower revenue, but higher earnings than Invivyd. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInvivyd$25.38M2.46-$169.93M-$0.92-0.574D Molecular Therapeutics$40K8,277.58-$160.87M-$3.53-2.01 Do analysts prefer IVVD or FDMT? Invivyd currently has a consensus target price of $3.85, suggesting a potential upside of 640.24%. 4D Molecular Therapeutics has a consensus target price of $30.40, suggesting a potential upside of 328.77%. Given Invivyd's stronger consensus rating and higher possible upside, analysts clearly believe Invivyd is more favorable than 4D Molecular Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invivyd 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.254D Molecular Therapeutics 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.64 Does the media refer more to IVVD or FDMT? In the previous week, Invivyd had 37 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 53 mentions for Invivyd and 16 mentions for 4D Molecular Therapeutics. Invivyd's average media sentiment score of 0.15 beat 4D Molecular Therapeutics' score of -0.10 indicating that Invivyd is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 18 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral 4D Molecular Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryInvivyd beats 4D Molecular Therapeutics on 10 of the 17 factors compared between the two stocks. Get Invivyd News Delivered to You Automatically Sign up to receive the latest news and ratings for IVVD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IVVD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IVVD vs. The Competition Export to ExcelMetricInvivydMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$62.49M$3.09B$5.82B$9.74BDividend YieldN/A2.23%3.84%4.09%P/E Ratio-0.5721.1431.1525.97Price / Sales2.46399.83475.57123.18Price / CashN/A43.0937.1558.38Price / Book1.448.079.116.39Net Income-$169.93M-$54.72M$3.26B$265.66M7 Day Performance-26.45%2.62%2.11%1.98%1 Month Performance-31.57%7.63%5.12%1.33%1 Year Performance-40.77%13.11%31.25%21.15% Invivyd Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IVVDInvivyd4.0285 of 5 stars$0.52-1.5%$3.85+640.2%-39.9%$62.49M$25.38M-0.57100Trending NewsShort Interest ↓Analyst RevisionFDMT4D Molecular Therapeutics2.1396 of 5 stars$7.27+0.1%$30.40+318.2%-54.9%$339.06M$40K-2.06120INBXInhibrx Biosciences1.7406 of 5 stars$23.87+2.3%N/A+85.1%$337.95M$200K-2.26166Analyst ForecastShort Interest ↓CADLCandel Therapeutics2.6155 of 5 stars$5.96-2.1%$22.00+269.1%+10.1%$334.31M$120K-8.6460LRMRLarimar Therapeutics2.2639 of 5 stars$3.90-2.7%$18.43+372.5%-54.7%$331.94MN/A-2.5030RCKTRocket Pharmaceuticals4.8877 of 5 stars$3.03-0.7%$16.33+439.1%-81.4%$329.11MN/A-1.21240Analyst ForecastAnalyst RevisionAMRNAmarin0.2717 of 5 stars$16.17+3.3%$12.00-25.8%+22.1%$324.07M$228.61M-4.41360Positive NewsALDXAldeyra Therapeutics2.1231 of 5 stars$5.44+0.9%$9.50+74.6%+9.7%$322.84MN/A-6.4010ALTAltimmune3.2899 of 5 stars$3.56-1.9%$17.40+388.8%-48.6%$320.37M$20K-3.0250Trending NewsCTMXCytomX Therapeutics4.0795 of 5 stars$2.12+11.0%$5.75+171.2%+59.8%$314.98M$138.10M3.79170High Trading VolumeCGCCanopy Growth0.7855 of 5 stars$1.37+5.4%N/A-80.6%$311.80M$225.65M-0.453,150Positive NewsShort Interest ↑Gap Up Related Companies and Tools Related Companies FDMT Competitors INBX Competitors CADL Competitors LRMR Competitors RCKT Competitors AMRN Competitors ALDX Competitors ALT Competitors CTMX Competitors CGC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IVVD) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invivyd With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access